Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.


Clinical Trial Description

Viral reactivation and infection is a major cause of morbidity in immunocompromised patients (including HSCT recipients). In this study we will draw blood from unrelated (third party) donors and use the blood to generate viral specific T-cells (VSTs) with specificity for Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (ADV), BK virus (BKV), and JC Virus. The VSTs will be infused into immunocompromised children with specific viral infections (EBV, CMV, ADV, BKV , or JC virus). Cells will be selected for infusion based on the recipient's HLA type and the viral specificity of the cells. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02532452
Study type Interventional
Source Children's Hospital Medical Center, Cincinnati
Contact Jamie Wilhelm
Phone (513) 803-1102
Email Jamie.Wilhelm@cchmc.org
Status Recruiting
Phase Phase 2
Start date September 2, 2015
Completion date December 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Not yet recruiting NCT05953233 - School Inner City Air Study N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Completed NCT01570283 - ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus Phase 1/Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Recruiting NCT05246098 - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Recruiting NCT05603650 - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract N/A
Completed NCT04525456 - Immune Responses With Reduxium N/A
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT04267809 - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection Phase 2
Completed NCT00341081 - Validation of Self-Reported Needle Sharing Among Injection Drug Users N/A
Recruiting NCT04088916 - Proviral DNA as a Target for HIV-1 Resistance Analysis
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Terminated NCT00952185 - Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Active, not recruiting NCT04254991 - A Controlled, Blinded Study to Validate the Diagnostic Accuracy and Assess the Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the ED With Suspicion of Acute Infection
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Terminated NCT02696291 - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects Phase 1
Recruiting NCT02456610 - Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China Phase 1